GlassScriptPhysician profile
Jade Hoy
NPI 1528268703
$2,659.33
in general payments reported to CMS, 2019-2025
32 companies · $203 in 2025
The $203 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,418 · 2020: $333 · 2021: $52.14 · 2022: $325 · 2023: $315 · 2024: $13.68 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $512 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $511.52 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $556.00 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $414.36 | 2019-2025 | Trelegy Ellipta |
| Pfizer INC. | $230.83 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $227.67 | 2019-2025 | Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $163.12 | 2022-2023 | |
| Lilly USA, LLC | $114.74 | 2019-2023 | Mounjaro, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.15 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $80.51 | 2019 | |
| Abbvie INC. | $76.47 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.77 | 2019-2023 | Xifaxan |
| Janssen Pharmaceuticals, INC | $65.43 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.76 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $49.45 | 2019-2020 | |
| Intuitive Surgical, INC. | $44.93 | 2025 | |
| Astellas Pharma US INC | $43.13 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $43.11 | 2019 | |
| Assertio Therapeutics, INC. | $41.20 | 2019 | |
| Genentech USA, INC. | $31.73 | 2019-2020 | |
| Amgen INC. | $31.36 | 2019-2022 | |
| Adlon Therapeutics L.P. | $30.74 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $29.72 | 2019 | |
| Novartis Pharmaceuticals Corporation | $25.33 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $23.08 | 2019 | |
| Exact Sciences Corporation | $17.66 | 2023 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $16.01 | 2020 | |
| Dexcom, INC. | $15.72 | 2022 | |
| Mannkind Corporation | $13.52 | 2019 | |
| Allergan, INC. | $13.21 | 2020 | |
| Ironshore Pharmaceuticals INC. | $12.00 | 2022 | |
| Gilead Sciences, INC. | $12.00 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.44 | 2020 | |
| Antares Pharma, INC. | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jade Hoy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.